New study's big ask: Can amyloid clearing drugs halt Alzheimer's in high-risk patients?
This article was originally published in Scrip
Executive Summary
The slight hint of efficacy seen in one of two Phase III clinical trials for Eli Lilly's solanezumab in patients with mild Alzheimer's disease will be put to the test alongside a Phase II Lilly small molecule and Roche's Phase III gantenerumab in a study by the Washington University School of Medicine in St Louis, Missouri to determine whether therapies targeting amyloid-beta can prevent Alzheimer's in people with genetic predispositions for the disease.